1660318540197 Number2

Pharma in review: trending stories 9/13/19

Sept. 13, 2019

FDA commish frontrunner emerges

MD Anderson Cancer Center exec Stephen Hahn has emerged as the frontrunner for FDA commissioner. 

Mallinckrodt offloads BioVectra for $250 million
Mallinckrodt will sell its subsidiary, BioVectra, to an affiliate of H.I.G. Capita for $250 million.
Amgen experimental lung cancer drug shows promise

More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug.

Novartis investigational lung cancer therapy grabs breakthrough status

                  The U.S. FDA has granted Breakthrough Therapy designation to Novartis' capmatinib.

BMS Opdivo fails in brain cancer study

Bristol-Myers said its blockbuster immunotherapy failed to meet a main goal of a late-stage trial.